Given the centrality of MAPK signaling to KRAS-driven cancer, specifically the KRAS-mut cancers that have been the focus of nearly all preclinical and clinical studies, considerable effort has been made to develop combination therapies in which a secondary agent is added to a backbone of MAPK inhibition, most typically with pharmacologic inhibitors of MEK1/2. The gene discussed is MAP2K1; the disease is cancer.